Europese Unie - Sloveens - EMA (European Medicines Agency)

resilience biomanufacturing ireland limited - cepivo proti gripi (cel virion, inaktiviran), ki vsebuje antigen: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cepiva - preprečevanje gripe v uradno prijavljeni pandemični situaciji. pandemije gripe cepiva je treba uporabljati v skladu z uradnimi smernice.

Europese Unie - Sloveens - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - deaktiviran virus gripe, ki vsebuje antigen: a / vietnam / 1194/2004 (h5n1), podoben sevu (nibrg-14) - influenza, human; immunization; disease outbreaks - cepiva - aktivna imunizacija proti podtipu h5n1 virusa influenca a. ta navedba temelji na immunogenicity podatkov iz zdravih predmetov iz 18. leta starosti dalje po uporabi zdravila dva odmerka cepiva, pripravljeni iz a/vietnam/1194/2004 nibrg-14 (h5n1) (glej točko 5. prepandemic cepiva proti gripi (h5n1) (split virion, inaktivirano, adjuvanted) glaxosmithkline biologicals 3. 75 µg je treba uporabljati v skladu z uradnimi smernice.

Europese Unie - Sloveens - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1), podoben sevu (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - cepiva - aktivna imunizacija proti podtipu h5n1 virusa influence. ta navedba temelji na immunogenicity podatkov iz zdravih predmetov iz 18. leta starosti dalje po uporabi zdravila dva odmerka cepiva, pripravljene s h5n1 podtipa sevi. prepandrix je treba uporabljati v skladu z uradnimi smernice.

Europese Unie - Sloveens - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - cepiva - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - cepiva - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcije respiratornih sincicijskih virusov - cepiva - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. glej poglavja 4. 2 in 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

merck sharp & dohme b.v. - cepivo proti humanim papilomavirusom [tipi 6, 11, 16, 18, 31, 33, 45, 52, 58] (rekombinantni, adsorbirani) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - papillomavirus cepiva - gardasil 9 je označen za aktivno imunizacijo posameznikov v starosti od 9 let proti naslednje hpv bolezni:premalignant poškodbah in raka, ki vplivajo na materničnem vratu, vulva, vagina in anus, ki jih povzročajo cepiva proti hpv typesgenital bradavice (condyloma acuminata), ki jih povzročajo posebne hpv tipov. glej poglavja 4. 4 in 5. 1 za pomembne informacije o podatkih, ki podpirajo te navedbe. uporaba gardasil 9 mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

bavarian nordic a/s - modificirani vakciniji virusa ankara - bavarska nordijska bolezen (mva-bn) - smallpox vaccine; monkeypox virus - druga virusna cepiva, - active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4. 4 in 5. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

Europese Unie - Sloveens - EMA (European Medicines Agency)

ceva santé animale - inaktivirana cepiva coxiella burnetii, sev devet milj - immunologicals for bovidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - goats; cattle - cattle: , for the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of coxiella burnetii in these animals via milk and vaginal mucus. , onset of immunity: not established. , duration of immunity: 280 days after completion of the primary vaccination course. , goats: , for the active immunisation of goats to reduce abortion caused by coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. , onset of immunity: not established. , duration of immunity: one year after completion of the primary vaccination course.